Tag Archives: care

Rhumbline Advisers Trims Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Diabetes News
Tandem Diabetes Care logo

[ad_1]

Rhumbline Advisers decreased its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDMFree Report) by 6.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 177,613 shares of the medical device company’s stock after selling 11,895 shares during the quarter. Rhumbline Advisers owned approximately 0.27% of Tandem Diabetes Care worth $7,213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. PNC Financial Services Group Inc. increased its position in Tandem Diabetes Care by 2.7% in the first quarter. PNC Financial Services Group Inc. now owns 6,246 shares of the medical device company’s stock worth $726,000 after buying an additional 164 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Tandem Diabetes Care by 3.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,616 shares of the medical device company’s stock worth $654,000 after acquiring an additional 184 shares during the period. State of Wyoming boosted its stake in shares of Tandem Diabetes Care by 45.8% in the fourth quarter. State of Wyoming now owns 821 shares of the medical device company’s stock worth $37,000 after acquiring an additional 258 shares during the period. Quadrant Capital Group LLC boosted its stake in shares of Tandem Diabetes Care by 53.5% in the fourth quarter. Quadrant Capital Group LLC now owns 841 shares of the medical device company’s stock worth $38,000 after acquiring an additional 293 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Tandem Diabetes Care by 0.3% in the second quarter. Legal & General Group Plc now owns 97,817 shares of the medical device company’s stock worth $5,790,000 after acquiring an additional 318 shares during the period.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $27.25 on Wednesday. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -7.83 and a beta of 0.87. Tandem Diabetes Care, Inc. has a 1 year low of $23.60 and a 1 year high of $59.91. The business has a 50 day simple moving average of $29.10 and a 200-day simple moving average of $32.91. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.38 and a quick ratio of 3.53.

Tandem Diabetes Care (NASDAQ:TNDMGet Free Report) last issued its quarterly earnings results on Thursday, August 3rd. The medical device company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.24. Tandem Diabetes Care had a negative return on equity of 20.29% and a negative net margin of 28.40%. The firm had revenue of $195.92 million for the quarter, compared to the consensus estimate of $201.62 million. Equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

TNDM has been the subject of a number of recent analyst reports. Robert W. Baird dropped their price objective on Tandem Diabetes Care from $33.00 to $32.00 and set a “neutral” rating for the company in a research note on Monday, August 21st. TD Cowen dropped their price objective on Tandem Diabetes Care from $52.00 to $34.00 and set an “outperform” rating for the company in a research note on Friday, August 4th. Citigroup dropped their price objective on Tandem Diabetes Care from $33.00 to $31.00 and set a “neutral” rating for the company in a research note on Monday, August 21st. StockNews.com initiated coverage on Tandem Diabetes Care in a research note on Thursday, August 17th. They set a “hold” rating for the company. Finally, Barclays dropped their price target on Tandem Diabetes Care from $71.00 to $62.00 and set an “overweight” rating for the company in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus price target of $46.80.

View Our Latest Stock Report on TNDM

About Tandem Diabetes Care

(Free Report)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Articles

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Tandem Diabetes Care, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tandem Diabetes Care wasn’t on the list.

While Tandem Diabetes Care currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

[ad_2]

Source link

Diabetes patient persists on hospice care without medication |

Diabetes News

[ad_1]

FROM NORTH AMERICA SYNDICATE, 300 W 57th STREET, 15th FLOOR, NEW YORK, NY 10019

CUSTOMER SERVICE: (800) 708-7311 EXT. 236

TO YOUR GOOD HEALTH #12345_20221109

FOR RELEASE WEEK OF NOV. 7, 2022 (COL. 3)

BYLINE: By Keith Roach, M.D.

TITLE: Diabetes patient persists on hospice care without medication

DEAR DR. ROACH: My dad has been on hospice care for several months now. He had an untreated wound infection that was not responding to meds, so he went on hospice. Also, his wife died, and he lost the will to live after that.

His sugars are well into the 400s. He is on pain meds and nothing else. His doctor says he should not have lasted this long, medically speaking. He gave me no other explanation except a shrug. His spirits are OK, but I fear something else will get him in the end, like bed sores, pneumonia, a fall or COVID. Is it normal for a diabetes patient who no longer takes their medication to linger like this? He is not suffering per se, but quality of life is not good either. — H.D.

ANSWER: The goal of hospice care is to provide comfort to a person in the last phase of their life. If your father was thought by his physician to have a condition that was likely to end his life (normally, an expectation of end of life coming within six months is a necessary condition for hospice care), and he made up his mind to choose this option (and understood the consequences of that action), then hospice is a reasonable choice.

Elevated blood sugars in people in hospice care are common. They are often not treated, as they usually do not cause symptoms. Elevated blood sugars over months (or years) predispose people with diabetes to complications, including infection, heart disease and stroke, but in a person in hospice care, these considerations are less important than the overall goal of reducing suffering. Medications are given orally whenever possible and, again, only to relieve symptoms.

Something will indeed “get him in the end,” as it will for all of us. People in hospice care have accepted that. It can be hard for family members, especially when there is not an immediately terminal disease like cancer associated with the hospice care.

DEAR DR. ROACH: My wife was just diagnosed with Paget’s disease of the breast. Is it true that surgery is the only option for treatment? We’ve never heard of this condition. The biopsy shows no cancer beyond the nipple area. — B.W.

ANSWER: Paget’s disease of the breast is an uncommon type of breast cancer almost only ever found in women (the more common type of breast cancer is found in men about 1% of the time, but PDB is extremely rare in men). The disease looks like a scaly or raw lesion on the nipple, which usually spreads to the areola around the nipple. Most women have itchiness, pain or burning, which often starts before — often months before — any skin changes. A careful exam and mammogram should be performed by an expert in women with symptoms of PDB, or with something abnormal she can see or feel on the nipple. The prognosis is much better in women who do not have a mass that can be felt on exam.

Surgery is almost always part of the treatment plan. Depending on the stage of the disease, some women will need a mastectomy, but in some cases, women can be treated with breast-conserving surgery (also called “lumpectomy”) followed by radiation treatment. There is no standard recommendation on medications, such as tamoxifen, in the treatment of PDB.

* * *

Dr. Roach regrets that he is unable to answer individual letters, but will incorporate them in the column whenever possible. Readers may email questions to ToYourGoodHealth@med.cornell.edu or send mail to 628 Virginia Dr., Orlando, FL 32803.

(c) 2022 North America Syndicate Inc.

All Rights Reserved

[ad_2]

Source link